Has Travis Richardson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $87,138 in general payments to Travis Richardson, MD across 258 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Travis Richardson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Travis Richardson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Travis Richardson, MD

Cardiovascular Disease · Nashville, TNNPI 1558687806

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Medtronic at 51.6% of the total. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$87,138in general payments, 2019–2025

Across 258 payments — averaging $337.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$45K
Biosense Webster, Inc.$22K
Boston Scientific$12K
Adagio Medical, Inc.$3K
Abbott$3K
Philips North America LLC$2K
plus $858 from 3 others

$1,184,815in research payments, 2019–2025

Across 103 payments — averaging $11,503 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$867K
Abbott$161K
Boston Scientific$157K

What the payments were for

Consulting fees$35,42841%
Speaking & faculty fees$19,87623%
Grants$2,3953%
Travel & lodging$20,72324%
Food & beverage$8,71610%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	148	$44,923
Biosense Webster, Inc.	40	$22,322
Boston Scientific	33	$11,797
Adagio Medical, Inc.	3	$2,612
Abbott	23	$2,529
Philips North America LLC	3	$2,098
Altathera Pharmaceuticals LLC	1	$600
Atricure, Inc.	5	$175
Biotronik Inc.	2	$83

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Carto 3$18,158
Farapulse$5,932
Micra$5,148
IVUS Systems$1,880
GENERAL BRADY$1,250
Watchman$1,145
EVERA MRI XT DR SURESCAN$1,036
RHYTHMIA$961
GENERAL - THERAPIES$889
Rhythmia Mapping System$817
AVEIR$753
Sotalol Hydrochloride$600
COBALT DR MRI SURESCAN$418
TACTICATH ABLATION CATHETER, SENSOR ENABLED$333
AURORA EV-ICD MRI SURESCAN$284
AMPLATZER AMULET$279
AZURE XT DR MRI SURESCAN$231
ENSITE$217
ARCTIC FRONT ADVANCE$153
EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$139

How this compares

$87,138 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee →

Medicare billing

Part B allowed, 2024

$272,772

Medicare patients

1,694

Services billed

3,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	459	$569,634
XareltoRivaroxaban	44	$45,426
Dofetilide	15	$7,709
FarxigaDapagliflozin Propanediol	12	$4,932
Metoprolol Succinate	245	$4,394
Propafenone Hcl ErPropafenone Hcl	19	$3,307
Amiodarone Hcl	121	$2,447
Flecainide Acetate	62	$2,404
Diltiazem 24hr Er (Cd)Diltiazem Hcl	51	$1,227
SotalolSotalol Hcl	61	$1,202
Mexiletine Hcl	12	$1,151
Metoprolol Tartrate	69	$643
Atorvastatin Calcium	34	$422
Losartan Potassium	21	$342
Furosemide	41	$282

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Nashville

Christopher EllisNashville$527K
Joann LindenfeldNashville$270K
Andrew ZurickNashville$231K
Mark ZenkerNashville$225K
George CrossleyNashville$197K
Joel PharesNashville$171K
Arvindh KanagasundramNashville$161K
Jessica HustonNashville$109K
Joshua BeckmanNashville$106K
Aniket RaliNashville$75K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →